Insider Selling: Zevra Therapeutics (NASDAQ:ZVRA) CEO Sells $853,580.00 in Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) CEO Neil Mcfarlane sold 91,000 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $9.38, for a total value of $853,580.00. Following the sale, the chief executive officer directly owned 364,350 shares in the company, valued at $3,417,603. This trade represents a 19.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Zevra Therapeutics Price Performance

Shares of NASDAQ:ZVRA opened at $8.94 on Thursday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 8.57 and a current ratio of 8.62. The firm has a market cap of $503.32 million, a price-to-earnings ratio of 19.02 and a beta of 0.99. The business has a 50-day simple moving average of $8.68 and a two-hundred day simple moving average of $9.40. Zevra Therapeutics, Inc. has a fifty-two week low of $6.19 and a fifty-two week high of $13.16.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.03. The firm had revenue of $26.06 million during the quarter, compared to analyst estimates of $26.64 million. Zevra Therapeutics had a net margin of 41.93% and a negative return on equity of 51.40%. On average, analysts expect that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Hedge Funds Weigh In On Zevra Therapeutics

Large investors have recently added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. boosted its position in shares of Zevra Therapeutics by 15.2% in the second quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock worth $36,720,000 after purchasing an additional 550,000 shares during the period. Vanguard Group Inc. boosted its holdings in Zevra Therapeutics by 4.4% in the 3rd quarter. Vanguard Group Inc. now owns 3,083,362 shares of the company’s stock worth $29,323,000 after buying an additional 130,676 shares during the period. Nantahala Capital Management LLC boosted its holdings in Zevra Therapeutics by 34.0% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,971,936 shares of the company’s stock worth $18,753,000 after buying an additional 500,000 shares during the period. Rubric Capital Management LP increased its stake in Zevra Therapeutics by 60.8% in the 2nd quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock worth $17,253,000 after buying an additional 740,584 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in Zevra Therapeutics by 0.8% during the second quarter. Geode Capital Management LLC now owns 1,242,386 shares of the company’s stock valued at $10,948,000 after acquiring an additional 9,275 shares during the period. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Analyst Upgrades and Downgrades

ZVRA has been the subject of several research analyst reports. HC Wainwright set a $26.00 price objective on Zevra Therapeutics in a report on Tuesday, December 30th. Wall Street Zen upgraded Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Zevra Therapeutics in a research note on Friday, January 9th. Cantor Fitzgerald cut their target price on shares of Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th. Finally, Canaccord Genuity Group reduced their target price on shares of Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a report on Thursday, November 6th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Zevra Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $22.80.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.